Avara obtains sterile manufacturing facility from Sandoz

| By | CDMO, Drug Manufacturing
0
74

Avara Pharmaceutical Services, a world-class contract development and manufacturing organization (CDMO), announced that it has closed on the transaction with Sandoz to acquire the largest sterile manufacturing facility for injectable medicines in Canada.

The proposed acquisition of the sterile manufacturing facility and the adjacent development center located in Boucherville, Quebec (Canada), became effective as of September 1st. It follows Avara’s acquisition of another sterile facility in the past year, one from Pfizer Inc. in Liscate (Italy), and one solid dose manufacturing facility from GlaxoSmithKline in Aiken, South Carolina (USA). It will bring the number of manufacturing and development sites operated by Avara worldwide to ten: two in Canada; three in the United States, including corporate headquarters; one in Puerto Rico; one in the UK; one in Ireland; one in Italy; and one in France.

The Boucherville site is the biggest injectables production facility in Canada and provides a number of strategic and lifesaving medicines to the Canadian healthcare system, mostly hospitals. As part of the asset purchase agreement, the parties signed a long-term supply contract to guarantee continuous supply of products manufactured in Boucherville. No impact on jobs will occur and Avara intends to invest in the site and pursue business development opportunities to optimize the plant’s utilization and expand its customer base.

Avara Pharmaceutical Services (Norwalk, Connecticut, USA) is an international pharmaceutical services company that delivers world-class contract manufacturing and technical services to the pharmaceutical industry. It has primary and secondary manufacturing facilities in North America and Europe and supplies products to all major markets around the world. Avara’s broad experience with supply chain, commercialization, product launch and product transfer allow us to sustain exemplary levels of product quality and regulatory compliance.